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Abstract: Vancomycin has usually been associated with nephrotoxicity. Generally, this  toxicity 
is presented as proximal tubular cells injury with or without necrosis and as acute intersti-
tial nephritis. However, development of both lesions is uncommonly described in literature. 
We present a case of vancomycin-induced nephrotoxicity resulting in both acute interstitial 
nephritis and tubular cells damage confirmed by renal biopsy. Peak and trough levels of 77.11 
and 63.60 μg /mL, respectively, were obtained at the first plasma determination. After 8 more 
plasma determinations and several hemodialysis sessions, vancomycin levels were undetectable 
1 month after therapy was stopped. To our knowledge, this is the case report with the highest 
vancomycin trough  levels developing both lesions and describing total vancomycin washout 
after a biopsy-proven vancomycin toxicity. In conclusion, early vancomycin therapeutic drug 
monitoring should be performed in order to avoid toxicities where, as seen in our patient, anti-
biotic exposure could last around 1 month after last dose administration.
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Introduction
Vancomycin is a time-dependent antibiotic with bactericidal activity useful for treat-
ing patients with infections caused by Gram-positive microorganisms, including 
methicillin-resistant Staphylococcus aureus. It presents a 2 or 3 compartment phar-
macokinetic profile and high interindividual variability, which result in the need for a 
routine therapeutic drug monitoring (TDM). Adverse effects associated with the use of 
this antibiotic include mainly those related to infusion and nephrotoxicity. Currently, 
these toxicities are related to long periods of treatment, concomitant nephrotoxic 
agents, high dosages, and high vancomycin plasma trough levels.1
Vancomycin has usually been associated with nephrotoxicity; nevertheless, the 
direct damage caused by this glycopeptide is still unknown.2 Vancomycin-induced 
nephrotoxicity is characterized by acute tubular necrosis (ATN) or interstitial dam-
age, yet the majority of biopsy reports have described acute interstitial nephritis 
(ATIN) rather than ATN. This probably reflects publication bias; it indicates the 
existence of an allergic mechanism in some patients with vancomycin nephrotoxic-
ity.3 In addition, to find both lesions on biopsy is uncommon.2 Also, poor definition 
of diagnosis may also limit early recognition and prompt intervention concerning 
vancomycin-induced nephrotoxicity.4 Since there are no clinical features or labo-
ratory findings that can confirm these pathologies, a renal biopsy is mandatory to 
obtain an accurate diagnosis.5
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We present a case of vancomycin nephrotoxicity with 
simultaneous histological lesions of ATIN and ATN con-
firmed by renal biopsy, originated by vancomycin intoxica-
tion related to the highest plasma trough levels described in 
literature.
Case report
Written informed consent was obtained from the patient 
described to have their case details published.
We report a case of vancomycin intoxication in a 46-year-
old man with no known drug allergies, with a weight of 85 kg 
(body mass index: 25.66 kg/m2) and normal renal function 
prior admission (glomerular filtration rate-modification of 
diet in renal disease [GFR-MDRD
4
]> 60 mL/min)
In July 2017, the patient was admitted to the emergency 
department due to headache, consciousness decrease, aphasia, 
and hypertensive crisis. He underwent a cranial computed 
tomography (CT) scanning, which diagnosed a massive 
cerebellar parenchymal hematoma and a vasogenic edema, 
with collapsing base cisterns and compressing the brainstem. 
Emergency neurosurgery was performed, setting up 2 external 
ventricular drains. Since the hypertensive crisis could not be 
controlled, the patient was admitted to the intensive care unit 
(ICU). The patient developed a multifactorial acute kidney 
injury (AKI) (serum creatinine [SCr]: 1.96 mg/dL, AKI 
AKIN 2). Ten days after intervention, the patient developed 
a fever which was suspicious for a probable central nervous 
system infection, so a sample of cerebrospinal fluid (CSF) 
was cultured. Also, blood, bronchoalveolar secretion, and 
urine cultures were performed. Firstly, the patient was treated 
with amoxicillin/clavulanate, and after persistant fever for 2 
days, the treatment was changed to piperacillin/tazobactam 
and new cultures were performed. On day 18, renal function 
returned to baseline values (SCr 1.4 mg/dL) but the patient’s 
consciousness level was reduced, and fever was still pres-
ent. CSF cultures were all negative, but compatible with 
bacterial ventriculitis; 4487 cells/mm3 (normal range [NR]: 
0–5 cells/mm3) with 90% polymorphonuclear disposition 
(NR: 1%–8%), 2200 red blood cells/mm3 (NR: 0–1 cells/
mm3), 72 mg/dL glucose (NR: 50–80 mg/dL), 7.3 mmol/L 
lactate (NR: 1–3 mmol/L), and 930 mg/dL proteins (NR: 
15–45 mg/dL); then, antimicrobial treatment was changed to 
meropenem and linezolid. After 3-week treatment, showing 
no fever, all cultures showing negative results, and normal-
ization of CSF biochemistry, the patient was discharged to a 
neurorehabilitation center.
Six days later, the patient was re-admitted to the emer-
gency department due to fever, decreased consciousness, 
and bronchial secretions. At the emergency department, the 
patient presented secondary seizures and was admitted to 
ICU, where a subdural collection was observed. The patient 
underwent a surgical intervention by neurosurgeons to 
evacuate the subdural hematoma. After 7 days in the ICU, the 
patient was stable and admitted to the neurosurgery unit. The 
patient remained hemodynamically stable with normal kidney 
function (SCr 1.2 mg/dL) and urine volume, 1.3–2.1 L/day, 
until day 10 from re-admission, when he started presenting 
tremors and small seizures. Physicians suspected postsurgical 
meningitis; therefore, a new sample of CSF was studied and 
it presented pathological features: 118 cells/mm3 (NR: 0–5 
cells/mm3) with 35% polymorphonuclear disposition (NR: 
1%–8%), 700 red blood cells/mm3 (NR: 0–1 cells/mm3), 23 
mg/dL glucose (NR: 50–80 mg/dL), 8.1 mmol/L lactate (NR: 
1–3 mmol/L), and 106.9 mg/dL proteins (NR: 15–45 mg/
dL); CSF was also cultured. However, no microorganism 
was isolated. Following the latest recommendations of the 
Infectious Diseases Society of America guidelines to treat 
meningitis, the patient was treated with ceftazidime 2 g/8 
hours and vancomycin 1 g/8 hours.6 After 5-day therapy, 
the patient presented an AKI AKIN 3 (SCr 3.05 mg/dL); so, 
vancomycin plasma levels (VPLs) were analyzed. Quantita-
tive microsphere system immunoassay was used to determine 
VPL, of which the lowest detectable level is 3 μg/mL and 
the highest is 100 μg/mL. Peak and trough levels of 77.11 
and 63.60 μg/mL, respectively, were obtained. After these 
results, vancomycin therapy was stopped and the patient 
was carried through a narrow TDM. Twenty-six hours after 
the last vancomycin dose, VPLs were still 61.53 μg/mL. 
A total of 9 VPL determinations were performed until the 
patient presented undetectable values. In each determination, 
pharmacokinetic parameters were calculated, presenting a 
maximum value of half-life time of 94.7 hours and distribu-
tion volume of 121 L. Also, area under the curve (AUC)
0-24h
 
with the last vancomycin dose was calculated, presenting an 
exposition of 2,096 μg/mL*h.
During the next few days, the patient developed severe renal 
impairment (SCr 10 mg/dL) which initiated renal replacement 
therapy at day 12 due to fluid overload. The patient received 
intermittent hemodialysis with a high permeability membrane 
(FX CorDiax 60, Fresenius Medical Care, Hesse, Germany). 
This membrane removes up to 50% of the substances with a 
molecular weight >550 Da (Vancomycin is 1,500 Da). Because 
of progressive renal impairment, despite vancomycin with-
drawal 12 days before, a renal biopsy was performed and an 
ATIN with severe tubular injury was observed; a diagnosis of 
vancomycin nephrotoxicity was made (SCr and VPL evolution 
shown at Figure 1). The patient did not receive steroid treatment 
because the delay of pathological diagnosis;  clinical suspicion 





were ATN. After 1 month without vancomycin therapy, the 
patient presented undetectable VPL at day 34. The patient 
underwent intermittent hemodialysis over 17 days with com-
plete recovery of renal function.
Discussion
It has been described that vancomycin trough plasma levels 
>20 μg/mL or AUC
0–24 h
 >700 μg/mL*h are related to nephro-
toxicity.7 Nevertheless, few cases of ATIN and tubular injury 
related to vancomycin are described as a biopsy confirmation 
is needed.
To our knowledge, only 2 other cases of biopsy-proven 
nephrotoxicity with both ATIN and tubular injury with VPL 
determinations are described. One case described by Katikaneni 
et al8 presented a biopsy-proven ATIN and ATN after vancomy-
cin treatment for a lung abscess, which after VPL determina-
tion showed a trough value of 49.4 μg/mL, lower than in our 
case. In the case published by Htike et al,9 bacteremia caused 
by a coagulase-negative staphylococcus, also ATIN and ATN 
was confirmed after renal biopsy; VPLs were extracted and 
peaked at 141 μg/mL. Even though this VPL is higher than in 
our case, there is no information about when this plasma level 
was extracted or if it was a peak or a trough level. Moreover, 
unlike our case, which had a total of 9 VPL determinations, the 
one they describe had just 1 VPL determination, and there is no 
information about total vancomycin washout and pharmaco-
kinetic parameters in patients presenting an AKI by ATN and 
ATIN. We were able to describe a total vancomycin washout 
of a month thanks to the narrow TDM performed.
From all cases, and referring to trough levels, VPL in 
our patient was the highest one (63.60 mcg/mL), in spite of 
the case published by Htike et al, which presented a plasma 
level of 141 μg/mL without specifying whether it was Cmax, 
Cmin, or a sample extracted at another time.
Unlike our case, the other cases did not calculate addi-
tional pharmacokinetic parameters. The AUC observed 
in our patient was well above the value considered as a 
predictor of nephrotoxicity (700 μg/mL*h). Our plasma 
determinations show that after renal damage, vancomycin 
can persist at high levels for a long time in the patient, 
with the possibility that this long exposure can cause more 
renal damage.
In conclusion, early vancomycin TDM should be per-
formed to avoid supratherapeutic plasma levels, which can 
lead to renal damage. As seen in our patient, antibiotic expo-
sure could last around 1 month after last dose administration, 
worsening the patient’s renal function several weeks after the 
end of therapy.
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Figure 1 sCr and VpL evolution.
Notes: sCr values from day 12 to 28 represented as a plateau due to the patient undergoing hemodialysis sessions. these values could be underestimated.
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